Senators want more insight into PBM practices and the role they play in the healthcare ecosystem.
Formulary Watch
Latest News
All News
Advertisement
Abarca's Nicole (Gupta) Bulochnik, Pharm.D., talks about how personalized medicine could be integrated into value-based care to accelerate uptake.
Javier Gonzalez, Pharm.D., at Abarca Health, talks about how value-based pricing arrangements can align incentives among stakeholders for specialty disease management.
The branded therapies were removed in favor of generics effective April 2023. CVS Caremark also added 13 generics to its Performance Drug List.
The hearing will discuss the role of PBMs in healthcare and the Pharmacy Benefit Manager Transparency Act, legislation that has been submitted by Sens. Maria Cantwell and Chuck Grassley.
No list price was provided for Rebyota but Ferring is offering copay and patient assistance programs.
The FDA indicated that Soligenix’s application for HyBryte, a novel photodynamic therapy, was incomplete.
Hospira/Pfizer’s potassium phosphates product alone may produce daily aluminum exposures of up to twice of the FDA-recommended limit for children.
If approved, Linzess would be the first and only FDA-approved prescription therapy for functional constipation in children 6 to 17 years of age. The PDUFA date is June 14th, 2023.
Chris Blackley, co-founder and chief executive officer of Prescryptive Health, discusses the laws that states that are implementing to restrict PBM practices and the impact on patients and employers.
Advertisement
Cibinqo is an oral, once-daily JAK1 inhibitor now approved for those 12 years of age and older.
High-priced gene therapies challenge payers to provide access. They are watching the products to be approved the first half of this year.
Conversion from accelerated to regular approval was based on long-term outcomes from a phase 1 trial, which demonstrated an overall response rate of 45.4%.
Eylea now also treats retinopathy of prematurity, a leading cause of childhood blindness worldwide.
In a real-world example, investigators found that lowered pricing of prescription drugs results in lower patient out-of-pocket costs, particularly for those patients with coinsurance.
In 2023, CVS executives expect revenue in pharmacy services to grow by 1% to 2% driven by generic and biosimilar launches.
In 2022, 12 states have enacted 19 pieces of legislation that put a variety of restrictions and requirements on pharmacy benefit managers (PBMs).
If approved, reproxalap would be the first inhibitor of RASP to treat patients with dry eye disease. The FDA PDUFA date is Nov. 23, 2023.
Takhzyro is the first therapy to prevent attacks of hereditary angioedema (HAE) in children ages 2 to under 6.
Zuranolone is a rapid-acting neuroactive steroid that can take effect in 14 days to treat patients with major depressive disorder and postpartum depression. The FDA has assigned a PDUFA action date of Aug. 5, 2023.
The products may be ineffective, unsafe and could prevent a person from seeking an appropriate diagnosis.
Trodelvy has been recommended as a preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network.
Tezspire is a biologic that specifically targets the inflammation associated with asthma.
Evernorth, Cigna’s pharmacy and benefits solutions division, contributed more than 75% of the company’s revenue last year.
The real impact may not likely be seen until after July when additional biosimilars referencing Humira are launched.
Daprodustat, now with the brand name of Jesduvroq, is a new oral therapy but it carries a boxed warning about the risk of cardiovascular events.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Virtual care replaces, not adds, Medicare visits for health systems, analysis shows
2
FDA approves $2.59 million gene therapy for SMA
3
Optum Rx removes reauthorizations from an additional 40 drugs
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5
